雷公藤多苷片联合西替利嗪治疗泛发性湿疹的临床研究

目的 探讨雷公藤多苷片联合西替利嗪治疗泛发性湿疹的临床疗效.方法 选取2018年5月—2021年6月昆山市第一人民医院收治的118例泛发性湿疹患者,按照随机数字表法将118例患者随机分成对照组和治疗组,每组各59例.对照组口服盐酸西替利嗪片,10 mg/次,1次/d.治疗组在对照组基础上口服雷公藤多苷片,1.0 mg/...

Clinical study on Tripterygium Glycosides Tablets combined with cetirizine in treatment of generalized eczema

Objective To systematically evaluate efficacy and safety of apatinib mesylate for advanced non-small cell lung cancer (NSCLC), for which to provide scientific proofs for clinical decision making. Methods The databases including: The Cochrane Library, Embase, PubMed, CNKI, CBM, VIP, Wanfang Data were searched from the inception to Jun 2021 to collect the randomized controlled trials (RCTs) related to the safety and efficacy of apatinib mesylate for the treatment of advanced NSCLC. Quality assessment and data extraction were conducted by two reviewers independently. Disagreement was resolved through discussion. and data analyses were performed with RevMan 5.2 software. Results A total of 17 RCTs were included, including 1 263 patients. There were 638 patients in treatment groups and 625 patients in the control group. The Meta-analysis results showed, compared with the control group, the total effective rate RR = 1.48, 95%CI (1.36, 1.62)], cytokeratin-19-fragment RR = -1.50, 95%CI (-1.75, -1.25)], carcinoembryonic antigen RR=-4.05,95%CI(-4.30,-3.80)],matrix metalloproteinase-9 RR = -401.98, 95%CI (-438.82, -365.13)], vascular endothelial growth factor RR = -192.54, 95%CI (-211.55, -173.53)] were significantly different in apatinib mesylate group (P < 0.000 01). The risk of gastrointestinal discomfort, proteinuria, leukopenia and oral mucositis in the treatment group was higher than that in the control group, but the difference was not statistically significant. Conclusion Based on the present clinical evidence, the Meta-analysis results indicate that the treatment efficacy of apatinib mesylate group is better than control group on treating advanced NSCLC, which is a standard treatment of advanced non-small cell lung cancer.